Reported 1 day ago
Corcept Therapeutics (CORT) announced pivotal results from its Phase 3 ROSELLA trial at the American Society of Clinical Oncology Annual Meeting, showing that the combination of relacorilant and nab-paclitaxel significantly improved progression-free survival in platinum-resistant ovarian cancer patients compared to nab-paclitaxel alone, with a 30% reduction in disease progression risk. The treatment demonstrated good tolerance and safety, with fewer incidence rates of ascites compared to the control group.
Source: YAHOO